EUVIMEDEUVIMED entdecken
Crossref

Targeted delivery of type I TGF-β receptor-mimicking peptide to fibrotic kidney for improving kidney fibrosis therapy via enhancing the inhibition of TGF-β1/Smad and p38 MAPK pathways

Xiaohua Wang, Xiaohui Liu, Liming Xu, Yuting Li, Bowen Zheng, Caiyun Xia, Jingru Wang, Haifeng Liu

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112483 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Xiaohua Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Heilongjiang Province Key Laboratory for Anti-fibrosis Biotherapy, Mudanjiang Medical University, Mudanjiang 157011, PR China; Laboratory of Pathogen…. Hauptthemen laut MEDLINE: Fibrosis, Transforming Growth Factor beta1, p38 Mitogen-Activated Protein Kinases, Kidney. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 59 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal fibrosis is a representative pathological feature of various chronic kidney diseases, and efficient treatment is needed. Interstitial myofibroblasts are a key driver of kidney fibrosis, which is dependent on the binding of TGF-β1 to type I TGF-β receptor (TβRI) and TGF-β1-related signaling pathways. Therefore, attenuating TGF-β1 activity by competing with TGF-β1 in myofibroblasts is an ideal strategy for treating kidney fibrosis. Recently, a novel TβRI-mimicking peptide RIPΔ demonstrated a high affinity for TGF-β1. Thus, it could be speculated that RIPΔ may be used for anti-fibrosis therapy. Platelet-derived growth factor β receptor (PDGFβR) is highly expressed in fibrotic kidney. In this study, we found that target peptide Z-RIPΔ, which is RIPΔ modified with PDGFβR-specific affibody ZPDGFβR, was specifically and highly taken up by TGF-β1-activated NIH3T3 fibroblasts. Moreover, Z-RIPΔ effectively inhibited the myofibroblast proliferation, migration and fibrosis response in vitro. In vivo and ex vivo experiments showed that Z-RIPΔ specifically targeted fibrotic kidney, improved the damaged renal function, and ameliorated kidney histopathology and renal fibrosis in UUO mice. Mechanistic studies showed that Z-RIPΔ hold the stronger inhibition of the TGF-β1/Smad and TGF-β1/p38 pathways than unmodified RIPΔ in vitro and in vivo. Furthermore, systemic administration of Z-RIPΔ to UUO mice led to minimal toxicity to major organs. Taken together, RIPΔ modified with ZPDGFβR increased its therapeutic efficacy and reduced its systemic toxicity, making it a potential candidate for targeted therapy for kidney fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FibrosisTransforming Growth Factor beta1p38 Mitogen-Activated Protein KinasesKidneyMice, Inbred C57BLSmad ProteinsAnimalsMiceNIH 3T3 CellsMaleSignal TransductionMyofibroblastsPeptidesKidney DiseasesReceptor, Transforming Growth Factor-beta Type IHumansDisease Models, AnimalCell Proliferation

Stichwörter der Autor:innen

AffibodyMyofibroblastsPlatelet-derived growth factor β receptorRenal fibrosisType I TGF-β receptor

Substanzen

Transforming Growth Factor beta1p38 Mitogen-Activated Protein KinasesSmad ProteinsPeptidesReceptor, Transforming Growth Factor-beta Type I

Autor:innen und Institutionen

  • Heilongjiang Province Key Laboratory for Anti-fibrosis Biotherapy, Mudanjiang Medical University, Mudanjiang 157011, PR China; Laboratory of Pathogenic Microbiology and Immunology, Mudanjiang Medical University, Mudanji…
  • Heilongjiang Province Key Laboratory for Anti-fibrosis Biotherapy, Mudanjiang Medical University, Mudanjiang 157011, PR China.
  • Laboratory of Pathogenic Microbiology and Immunology, Mudanjiang Medical University, Mudanjiang 157011, PR China.

Zitieren

APA

Wang, X., Liu, X., Xu, L., Li, Y., Zheng, B., Xia, C., Wang, J., & Liu, H. (2024). Targeted delivery of type I TGF-β receptor-mimicking peptide to fibrotic kidney for improving kidney fibrosis therapy via enhancing the inhibition of TGF-β1/Smad and p38 MAPK pathways. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112483

Vancouver

Wang X, Liu X, Xu L, Li Y, Zheng B, Xia C, et al. Targeted delivery of type I TGF-β receptor-mimicking peptide to fibrotic kidney for improving kidney fibrosis therapy via enhancing the inhibition of TGF-β1/Smad and p38 MAPK pathways. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112483

BibTeX
@article{Wang2024,
  author = {Wang, Xiaohua and Liu, Xiaohui and Xu, Liming and Li, Yuting and Zheng, Bowen and Xia, Caiyun and Wang, Jingru and Liu, Haifeng},
  title = {Targeted delivery of type I TGF-β receptor-mimicking peptide to fibrotic kidney for improving kidney fibrosis therapy via enhancing the inhibition of TGF-β1/Smad and p38 MAPK pathways},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112483}
}
Kostenlos starten →